Related Experiment Video

Updated: Jan 18, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant

Chandrakant S Gawli1, Narendra R Nagpure1, Bhatu R Patil1

  • 1R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.

Drug Development Research
|September 8, 2025
PubMed

Insights

Lazertinib, a new third-generation EGFR inhibitor, shows promise for non-small cell lung cancer (NSCLC) treatment. It offers improved efficacy and safety over Osimertinib, with better brain penetration for metastatic disease.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Non-small cell lung cancer (NSCLC) is a major cause of cancer mortality.
  • Epidermal growth factor receptor (EGFR) mutations drive NSCLC progression.
  • Third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) like Osimertinib improved outcomes but have cardiotoxicity concerns.

Purpose of the Study:

  • To highlight the pharmacological properties and clinical potential of Lazertinib.
  • To compare Lazertinib with Osimertinib regarding efficacy, safety, and resistance mechanisms.
  • To evaluate Lazertinib's potential as a next-generation EGFR inhibitor for NSCLC.

Main Methods:

  • Review of pharmacological properties and binding interactions of Lazertinib.
  • Comparative analysis of Lazertinib and Osimertinib based on existing data and clinical trials.
  • Assessment of efficacy in overcoming resistance mutations and safety profiles, including cardiotoxicity and CNS penetration.

Main Results:

  • Lazertinib demonstrates superior selectivity for mutant EGFR over wild-type EGFR, reducing off-target toxicities.
  • Comparative analyses indicate stronger inhibition of key EGFR mutations, superior pharmacokinetics, and lower cardiotoxicity risks for Lazertinib versus Osimertinib.
  • Lazertinib exhibits enhanced central nervous system (CNS) penetration, beneficial for brain metastases.

Conclusions:

  • Lazertinib represents a promising next-generation EGFR inhibitor for NSCLC treatment.
  • Its improved safety profile and efficacy, particularly in overcoming resistance and CNS penetration, position it as a valuable alternative to Osimertinib.
  • Ongoing clinical trials are crucial to further define Lazertinib's role in NSCLC therapy.
Keywords:
CNS penetrationEGFR‐TKILazertinibOsimertinibT790M mutationcardiotoxicitynon‐small cell lung cancer

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
453
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K